PATENT CLAIM ANALYSIS

Application Number: 16297271
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "182000"]

Abstract:
A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. in particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5-en-26-oic (3β,7α-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.

Claim (Index 19):
The method of  claim 18  wherein the cholestenoic acid is selected from 3\u03b2,7\u03b1-diHCA, 3\u03b2,7\u03b2-diHCA, 7\u03b1, 26-diHCO, 7\u03b1, 26-diHC, 3\u03b2-HCA and 26-HC.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 99.0
- Lexical Diversity: 1.63462
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14770313', '14425548', '13406092', '14976177', '14961823']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7595516098405246
- 35 USC 102 Novelty (BERT): 0.6817946211496881
- Combined Prediction Score: 0.751775910971441
- Mean Citation Score: 379.99412200000006
- Max Citation Score: 900.5553
- Similarity Product: 650.8324960383652

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test